Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Phase, Pharmacokinetic Clinical Study to Evaluate Cannabinoid-Based Gum With Dronabinol in Healthy Human Subjects

Next Previous
Trial Profile

A Multi-Phase, Pharmacokinetic Clinical Study to Evaluate Cannabinoid-Based Gum With Dronabinol in Healthy Human Subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nabiximols (Primary) ; Dronabinol
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Pharmacokinetics
  • Sponsors Axim Biotech

Most Recent Events

  • 25 Feb 2020 New trial record
  • 18 Feb 2020 According to an Axim Biotech media release, with the promising results of the first phase of this clinical trial, AXIM will proceed with the second phase of the study to allow the Company to draw further comparative conclusions.It will be comprised of 20 healthy human subjects who will receive single 5 mg, 10 mg and 20 mg doses of the Companys dronabinol chewing gum and a single 5 mg Marinol capsule.
  • 18 Feb 2020 Preliminary results (n=10) presented in an Axim Biotech media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top